Value Microcaps Motherboard

[whyme2005]

DYNT $1.4...Earnings tomorrow morning...Bulls and Bears frozen so far..i believe that the bulls will win tomorrow and in the weeks ahead.

http://stockcharts.com/gallery/?dynt

Keep an eye on DYNT...strong 1Q 2007 earnings/guidance are expected tomorrow...Target: $3+ within 3 months.

Guidance for 2Q 2007 will be even stronger. The CEO already said in the last CC that 2Q 2007 will be a breakout quarter.

The last time that happened, the stock went from $1.3 to $4+ from November to February....see the lower weekly chart above.

For 2007 management expects a 10%+ revenue growth due to an unprecedent number of new-generation products recently released. Net income will improve dramatically as well because the company plans to cut down the record 2006 R$D costs by about 5c/share to historical levels.

My revenue estimate for 1Q 2007 is of $5M+ and about 2 - 4c/share net income. This compares favorably with $4.3M in revenues reported in 1Q 2006 and a rare (although small $22K) loss. 1Q 2007 numbers should also beat 4Q 2006 handily both in revenues and net income.

DYNT will likely generate a net income of about 15c/share in 2007. This is because the margins for the new products will be higher and the company will reduce R&D expenses by about 5c/share

DYNT HIGHLIGHTS:

* DYNT IS THE LEADER IN LIGHT THERAPY FOR PAIN MANAGEMENT

* FDA APPROVED and PATENTED PRODUCTS

* PROFITABLE AND TRADING AT 0.5 P/S

* STRONG BALANCE SHEET

* STOCK BUYBACK IS ONGOING.

DYNT is one of the safest stock you will find under $2. The company believes the stock is too undervalued and they have a stock buyback that they activate when the stock reaches under $1.3. They bought over 50,000 shares this year and have money approved for about 250,000 more shares

DYNT predicted at least 10% revenue increase for 2007 compared to 2006. 2006 was a year of transition and they invested a record $1.7M in R&D. This led to the recent release of many new products....the highest number of new products in company history.

SELECTED COMPANY COMMENTS FROM 2006 EARNINGS RELEASE and CC

..."New products introduced during the past year include the Dynatron 702, a stand-alone light therapy device, as well as the new DX9 combination traction and light therapy system. The DX9 system combines the benefits of infrared light therapy using the Dynatron 702 with decompression therapy using the Company's TX900 Traction device. This unique combination of modalities has been reported to be highly effective in the treatment of back pain..."

"Looking ahead to fiscal 2007, we are pleased to have begun the year with the July 2006 introduction of the new Dynatron X3 infrared light therapy device," said Larry K. Beardall, executive vice president for sales and marketing. "In addition, we plan to introduce the much anticipated DX2 proprietary traction device soon. The DX2 incorporates patent-pending technology and will utilize the new T4 treatment table which is specially designed for traction and decompression therapies. The T4 treatment table is scheduled for introduction in November 2006."

The new DX2 is currently undergoing clinical beta testing and has been previewed at several national trade shows. "Interest in the DX2 from practitioners at the national trade shows has been substantial," reported Beardall. "While the development effort has taken longer than anticipated, we believe this innovative approach to treating back pain will prove to be a great benefit to patients."


DYNT is the leader in light therapy technology for pain management. DYNT's Light therapy products are FDA-approved.

DYNT made big news 2 years ago when one of DYNT's light probe was used fix Terrell Owens foot. He was expected to miss the playoffs, however, thanks to DYNT therapy the psycho was able to play and shine big time in the Superbowl. They should used the probe to fix his brain instead